|Bid||52.00 x 2200|
|Ask||0.00 x 1100|
|Day's Range||70.37 - 70.94|
|52 Week Range||57.14 - 72.58|
|PE Ratio (TTM)||54.86|
|Forward Dividend & Yield||0.76 (1.08%)|
|1y Target Est||N/A|
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
The family office of billionaire George Soros trimmed its stake in Liberty Broadband Corp. in the first quarter, according to a regulatory filing on Tuesday. The filing also reflected Soros's previously disclosed stake of nearly 21.5 million shares in Vici Properties Inc. , the fund's second-largest holding. Soros also increased his stake in Aetna by 346,585 shares, and boosted its holdings of Baxter International Inc. by more than 468,000 shares.
Zacks.com highlights: Schweitzer-Mauduit International, Insight Enterprises, Baxter International, Fortinet and Comfort Systems USA
Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.
A 52-week high level generally works as an indicator for investors as stocks near that level are perceived to be winners. Notably, investors often wonder if the stock is overpriced considering the high price level. In fact, an investor might miss out on top gainers in an attempt to avoid the steep prices of stocks that are near the 52-week high mark. However, a stock can maintain the momentum and keep scaling new highs with time. Many a time, stocks hitting a 52-week high fail to scale higher despite potential due as investors fear that the stocks are overvalued and a price crash is impending.
BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.
We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.
Robust growth in Medicare and non-Medicare revenues at Amedisys' (AMED) Home Health and Hospice divisions boost the company's Q1 results.